Can Ozempic Help You Live Longer?

Two of the most prominent trends in healthcare — longevity medicine and weight-loss drugs — are increasingly converging.

For several years, a theory has circulated among biohackers and aging researchers that GLP-1 medications such as Ozempic or Zepbound might help people live longer. Online pharmacies are already promoting compounded versions of these drugs with claims that they could extend healthy lifespan, or health span. Until now, however, there has been very little academic research investigating this hypothesis.

One of the first studies to actually test this theory was published last month. It found that among people with HIV and lipohypertrophy — abnormal fatty deposits under the skin — eight months of treatment with semaglutide, the active ingredient in Ozempic, appeared to slow biological aging. This was assessed using blood tests that measure age-related biomarkers.

People with HIV often experience accelerated aging as a result of the infection and therefore represent a useful population for studying aging, according to Michael Corley, Associate Professor of Medicine at the Stein Institute for Research on Aging at the University of California, San Diego, who led the study.

The research was still preliminary, but according to Dr. Corley, it offered an opportunity to investigate an important question: Is there really a signal that justifies all the excitement surrounding these drugs?

Could Ozempic help you live longer?

Scientists are currently investigating whether GLP-1 medications could extend lifespan.

Interest in this possibility is based on several types of evidence.

First, there is now extensive research showing that GLP-1 medications improve metabolic health. They help regulate insulin and blood sugar levels and promote weight loss.

Several studies have also demonstrated beneficial effects on:

cardiovascular health;

the liver;

the kidneys.

Because these medications provide protection against conditions such as diabetes and cardiovascular disease — both major causes of death — GLP-1 drugs could, in a sense, already be regarded as longevity drugs.

“GLP-1 agonists reduce the incidence of age-related conditions that are associated with a shorter lifespan,” says Dr. Nicolas Musi, Director of the Diabetes and Aging Center at Cedars-Sinai in Los Angeles.

“You could therefore hypothesize that they may also extend lifespan and have beneficial effects on longevity,” he added.

Effects on cellular aging

Another reason researchers believe these medications may potentially extend lifespan is their effect on cellular health.

Metabolic health and aging are closely interconnected. Drugs that alter metabolic mechanisms may therefore also influence processes that determine how the body ages.

“Many of the metabolic pathways affected by diabetes medications are also fundamental pathways that regulate aging and lifespan,” according to Dr. Musi.

Other diabetes medications, such as metformin and SGLT2 inhibitors, are also being studied for their potential effects on longevity, although the results so far have been mixed.

Reduced inflammation

GLP-1 medications also appear to influence other fundamental cellular changes that occur during aging.

One of the most important of these is inflammation.

“We know that they have a significant anti-inflammatory effect, and we know that inflammation is one of the factors that accelerates aging,” says Dr. Thomas Blackwell, Professor of General Internal Medicine at the University of Texas Medical Branch in Galveston.

But there is an important caveat

Although all of this sounds promising, researchers point to one very important limitation:

There is currently little to no evidence showing that GLP-1 medications provide benefits in people who are metabolically healthy.

There are not even data demonstrating that these medications extend lifespan in healthy laboratory animals such as mice.

Dr. Richard Miller, Professor of Pathology at the University of Michigan and leader of a major research program studying potential anti-aging drugs in mice, says that this is largely due to practical reasons.

The currently available GLP-1 medications do not work in mice in exactly the same way as they do in humans, or they need to be administered by injection. Injecting mice every week for several years is difficult to carry out in practice.

Potential disadvantages in older adults

There are also concerns that GLP-1 medications may have certain effects that could actually be harmful in older people.

One of the main concerns is loss of muscle mass.

Weight loss with GLP-1 medications can be accompanied by loss of muscle tissue. This is particularly important in older adults because reduced muscle mass is associated with an increased risk of frailty.

Rapid weight loss may also lead to:

a reduction in bone density;

an increased risk of osteoporosis.

New clinical trials

Several clinical trials are now beginning in which GLP-1 medications will be tested for their effects on different features of aging.

Researchers will examine factors including:

inflammatory markers;

biological aging clocks;

muscle strength;

walking speed;

other measures of physical function.

At least one of these studies, however, will again not involve completely healthy older adults.

Participants must meet the criteria for receiving a prescription for an anti-obesity medication.

For example, this may mean:

a BMI of 27 or higher combined with an additional condition such as hypertension.

According to Dr. Blackwell, who is leading this study, this nevertheless represents a very large population.

Those criteria apply to “a whole lot of Americans.”

In summary

The hypothesis that GLP-1 medications such as semaglutide could extend healthy lifespan is biologically plausible.

The main rationale is:

weight loss → improved metabolic health → less diabetes and cardiovascular disease → potentially lower mortality

but possibly also:

reduced chronic inflammation → effects on biological aging processes.

However, the crucial question remains unanswered:

Do GLP-1 medications actually extend the lifespan of people who are otherwise healthy?

At present, there is still insufficient evidence to answer that question.

In older adults, potential disadvantages such as loss of muscle mass and bone mass must also be taken into account, meaning that the overall effect on healthy aging remains unclear.